Induces Immune Response: When the mumps virus vaccine is administered, the attenuated virus replicates in the body at a limited rate. This limited replication is enough to trigger an immune response but not strong enough to cause mumps.
Humoral Immunity: The vaccine primarily stimulates the production of specific antibodies against the mumps virus. These antibodies, called anti-mumps antibodies, circulate in the bloodstream and target the virus, neutralizing and preventing its spread.
Cellular Immunity: Besides humoral immunity, the mumps vaccine induces cellular immune responses. This involves the activation of T-lymphocytes (T-cells) that recognize and destroy cells infected with the mumps virus, helping to clear the virus from the body.
Memory Immune Response: Like other live vaccines, the mumps virus vaccine live also induces memory immune responses. Memory B-cells and T-cells are formed during the immune response, providing long-term immunity against the mumps virus. These memory cells “remember” the virus and can rapidly mount a defense if the person is exposed to the virus in the future.
Spectrum:
The mumps virus vaccine live provides a broad spectrum of protection against mumps infection and its potential complications, which include:
Prevention of mumps: The primary action of the mumps virus vaccine is to prevent mumps infection. By developing immunity through vaccination, the body can effectively fight off the mumps virus if exposed to it in the future.
Parotitis Prevention: mumps typically causes painful swelling of the salivary glands, particularly the parotid glands, resulting in parotitis. The vaccine’s ability to prevent mumps reduces the risk of parotitis and its associated discomfort and complications.
Orchitis and Oophoritis Prevention: mumps can lead to complications like orchitis (inflammation of the testicles) in males and oophoritis (inflammation of the ovaries) in females. Vaccination against mumps helps prevent these complications.
Meningitis Prevention: In some cases, mumps can lead to viral meningitis, an inflammation of the membranes surrounding the brain and spinal cord. The vaccine reduces the risk of mumps-related viral meningitis by preventing mumps infection.
DRUG INTERACTION
mumps virus vaccine, live
&
mumps virus vaccine, live +
No drug interaction found for mumps virus vaccine, live and .
Frequency not defined
Erythema
Wheal
Pain
Erythema
Anaphylaxis
Vasculitis
Urticaria
Rash
Nausea
Pancreatitis
Purpura
Muscle pain
Black Box Warning:
None
Contraindication/Caution:
Contraindications:
Severe allergy
Immunodeficiency
Pregnancy
Cautions:
Recent blood product administration
History of thrombocytopenia
Mild to moderate illness
Pregnancy consideration:
US FDA Pregnancy category: C
Breastfeeding warnings:
The excretion of the drug in breast milk is unknown.
Pregnancy category:
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Pharmacology:
Immunogenicity: The primary pharmacological action of the mumps virus vaccine live is its ability to induce an immune response. When the vaccine is administered, the weakened mumps virus replicates at a limited rate at the injection site.
Activation of Immune Response: The attenuated virus in the body triggers the immune system. The immune cells recognize the viral antigens and initiate an immune response against the virus.
Humoral Immunity: The vaccine primarily stimulates the production of specific antibodies against the mumps virus. These antibodies, known as anti-mumps antibodies, circulate in the bloodstream and other body fluids, targeting and neutralizing the virus.
Cellular Immunity: Besides humoral immunity, the mumps virus vaccine induces cellular immune responses. It activates T-lymphocytes (T-cells) that recognize and destroy cells infected with the mumps virus, helping to clear the virus from the body.
Memory Immune Response: Like other live vaccines, the mumps virus vaccine live induces memory immune responses. Memory B-cells and T-cells are formed during the immune response, providing long-term immunity against the mumps virus. These memory cells “remember” the virus and can rapidly mount a defense if the person is exposed to the virus in the future.
Top of Form
Pharmacodynamics:
Antigen Presentation: When the rubella virus vaccine is administered, the attenuated live virus replicates in the body at a limited rate. The viral particles are taken up by antigen-presenting cells (APCs).
Activation of Adaptive Immune Response: The antigen-presenting cells process the viral antigens and present them to T-lymphocytes (T-cells) and B-lymphocytes (B-cells). This interaction stimulates the adaptive immune response, which is highly specific to the rubella virus.
B-Cell Activation and Antibody Production: B-cells are activated by the presented antigens, leading to their proliferation and differentiation into plasma cells. Plasma cells secrete specific antibodies, called anti-rubella antibodies, into the bloodstream.
Humoral Immunity: The antibodies produced in response to the rubella virus vaccine are critical for humoral immunity. These antibodies circulate in the blood and other body fluids, ready to neutralize the rubella virus if it enters the body.
Memory Immune Response: One of the crucial aspects of the rubella vaccine life is its ability to induce memory immune responses. Memory B-cells and T-cells are formed during the immune response, providing long-term immunity against the rubella virus. These memory cells “remember” the rubella virus and can rapidly mount a defense if the individual is exposed to the virus again.
Cellular Immunity: Besides humoral immunity, the live rubella vaccine elicits cellular immune responses. T-cells play a crucial role in cellular immunity by recognizing and destroying cells infected with the rubella virus. This helps to clear the virus from the body and prevent its further spread.
Pharmacokinetics:
Absorption
The mumps virus vaccine live is usually administered through subcutaneous or intramuscular injection. After injection, the attenuated virus replicates in the body at a limited rate at the injection site.
Distribution:
The vaccine virus may disseminate from the injection site to other body parts through the lymphatic system. As the immune response is triggered, various immune cells, such as B-cells and T-cells, encounter the viral antigens and become activated, producing specific antibodies against the mumps virus.
Metabolism:
As a live vaccine, the mumps virus vaccine does not undergo typical metabolic processes like drugs. Instead, the attenuated virus replicates in a limited manner, serving as the antigen to stimulate the immune response. This immune response is what confers protection against mumps in the future.
Elimination and Excretion:
The attenuated rubella virus in the vaccine does not persist in the body indefinitely. Over time, the replication of the virus decreases, and it is eventually cleared from the body.
Administration:
Healthcare Setting: The mumps virus vaccine live is usually administered in a healthcare setting, such as a doctor’s office, clinic, or vaccination center. Trained healthcare professionals, such as nurses or doctors, perform the vaccination.
Age for Vaccination: The mumps virus vaccine live is commonly given to children as part of the recommended childhood vaccination schedule. It is often administered as part of a combination vaccine known as the measles, mumps, and rubella (MMR) or the measles, mumps, rubella, and varicella (MMRV) vaccine.
Booster Doses: In some countries, a mumps virus vaccine booster dose may be recommended for specific age groups or individuals. Booster doses help maintain long-term immunity against mumps.
Recommended Schedule: The recommended schedule for the mumps virus vaccine varies by country and health guidelines. In many countries, the first dose of the MMR or MMRV vaccine is given around 12 to 15 months, with a second dose between 4 and 6 years of age. However, specific recommendations may differ, so it is essential to follow the schedule local health authorities provide.
Catch-up Vaccination: Individuals who have not received the mumps virus vaccine during childhood can still get vaccinated. Catch-up vaccination may be recommended for adolescents and adults who did not receive the vaccine in childhood or have incomplete vaccination records.
Patient information leaflet
Generic Name: mumps virus vaccine, live
Pronounced as: mumps-VYE-rus-VAX-een, lyve
Why do we use the mumps virus vaccine live?
Prevention of mumps: The primary goal of administering the mumps virus vaccine is to prevent mumps infections. By vaccinating individuals against mumps, the vaccine helps reduce the virus’s spread in the population.
Control of Outbreaks: mumps is a highly contagious disease that can cause outbreaks, especially in communities with low vaccination rates. The vaccine plays a crucial role in controlling and preventing outbreaks, limiting the number of cases, and reducing transmission.
Herd Immunity: Widespread vaccination against mumps contributes to herd immunity. When a significant portion of the population is immune to the virus, it creates a protective barrier, reducing the likelihood of the virus spreading to vulnerable individuals who cannot receive the vaccine, such as those with weakened immune systems or certain medical conditions.
Prevention of Complications: mumps can lead to complications, particularly in adolescents and adults. These complications may include orchitis and oophoritis, meningitis (inflammation of the membranes surrounding the brain and spinal cord), and encephalitis (inflammation of the brain). Vaccination against mumps helps prevent these complications.
Long-Lasting Immunity: The mumps virus vaccine live elicits a robust and long-lasting immune response. After receiving the vaccine, most individuals develop protective immunity against mumps, lasting many years or even a lifetime.
Cost-Effective Public Health Measure: Vaccinating against mumps is a cost-effective public health intervention. It helps prevent the economic burden associated with mumps infections and its complications by reducing the need for medical care and hospitalization.
No Drug Intearction Found. for mumps virus vaccine, live and .
Actions and Spectrum
Actions:
Induces Immune Response: When the mumps virus vaccine is administered, the attenuated virus replicates in the body at a limited rate. This limited replication is enough to trigger an immune response but not strong enough to cause mumps.
Humoral Immunity: The vaccine primarily stimulates the production of specific antibodies against the mumps virus. These antibodies, called anti-mumps antibodies, circulate in the bloodstream and target the virus, neutralizing and preventing its spread.
Cellular Immunity: Besides humoral immunity, the mumps vaccine induces cellular immune responses. This involves the activation of T-lymphocytes (T-cells) that recognize and destroy cells infected with the mumps virus, helping to clear the virus from the body.
Memory Immune Response: Like other live vaccines, the mumps virus vaccine live also induces memory immune responses. Memory B-cells and T-cells are formed during the immune response, providing long-term immunity against the mumps virus. These memory cells “remember” the virus and can rapidly mount a defense if the person is exposed to the virus in the future.
Spectrum:
The mumps virus vaccine live provides a broad spectrum of protection against mumps infection and its potential complications, which include:
Prevention of mumps: The primary action of the mumps virus vaccine is to prevent mumps infection. By developing immunity through vaccination, the body can effectively fight off the mumps virus if exposed to it in the future.
Parotitis Prevention: mumps typically causes painful swelling of the salivary glands, particularly the parotid glands, resulting in parotitis. The vaccine’s ability to prevent mumps reduces the risk of parotitis and its associated discomfort and complications.
Orchitis and Oophoritis Prevention: mumps can lead to complications like orchitis (inflammation of the testicles) in males and oophoritis (inflammation of the ovaries) in females. Vaccination against mumps helps prevent these complications.
Meningitis Prevention: In some cases, mumps can lead to viral meningitis, an inflammation of the membranes surrounding the brain and spinal cord. The vaccine reduces the risk of mumps-related viral meningitis by preventing mumps infection.
Frequency not defined
Erythema
Wheal
Pain
Erythema
Anaphylaxis
Vasculitis
Urticaria
Rash
Nausea
Pancreatitis
Purpura
Muscle pain
Black Box Warning:
None
Contraindication/Caution:
Contraindications:
Severe allergy
Immunodeficiency
Pregnancy
Cautions:
Recent blood product administration
History of thrombocytopenia
Mild to moderate illness
Pregnancy consideration:
US FDA Pregnancy category: C
Breastfeeding warnings:
The excretion of the drug in breast milk is unknown.
Pregnancy category:
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Pharmacology:
Immunogenicity: The primary pharmacological action of the mumps virus vaccine live is its ability to induce an immune response. When the vaccine is administered, the weakened mumps virus replicates at a limited rate at the injection site.
Activation of Immune Response: The attenuated virus in the body triggers the immune system. The immune cells recognize the viral antigens and initiate an immune response against the virus.
Humoral Immunity: The vaccine primarily stimulates the production of specific antibodies against the mumps virus. These antibodies, known as anti-mumps antibodies, circulate in the bloodstream and other body fluids, targeting and neutralizing the virus.
Cellular Immunity: Besides humoral immunity, the mumps virus vaccine induces cellular immune responses. It activates T-lymphocytes (T-cells) that recognize and destroy cells infected with the mumps virus, helping to clear the virus from the body.
Memory Immune Response: Like other live vaccines, the mumps virus vaccine live induces memory immune responses. Memory B-cells and T-cells are formed during the immune response, providing long-term immunity against the mumps virus. These memory cells “remember” the virus and can rapidly mount a defense if the person is exposed to the virus in the future.
Top of Form
Pharmacodynamics:
Antigen Presentation: When the rubella virus vaccine is administered, the attenuated live virus replicates in the body at a limited rate. The viral particles are taken up by antigen-presenting cells (APCs).
Activation of Adaptive Immune Response: The antigen-presenting cells process the viral antigens and present them to T-lymphocytes (T-cells) and B-lymphocytes (B-cells). This interaction stimulates the adaptive immune response, which is highly specific to the rubella virus.
B-Cell Activation and Antibody Production: B-cells are activated by the presented antigens, leading to their proliferation and differentiation into plasma cells. Plasma cells secrete specific antibodies, called anti-rubella antibodies, into the bloodstream.
Humoral Immunity: The antibodies produced in response to the rubella virus vaccine are critical for humoral immunity. These antibodies circulate in the blood and other body fluids, ready to neutralize the rubella virus if it enters the body.
Memory Immune Response: One of the crucial aspects of the rubella vaccine life is its ability to induce memory immune responses. Memory B-cells and T-cells are formed during the immune response, providing long-term immunity against the rubella virus. These memory cells “remember” the rubella virus and can rapidly mount a defense if the individual is exposed to the virus again.
Cellular Immunity: Besides humoral immunity, the live rubella vaccine elicits cellular immune responses. T-cells play a crucial role in cellular immunity by recognizing and destroying cells infected with the rubella virus. This helps to clear the virus from the body and prevent its further spread.
Pharmacokinetics:
Absorption
The mumps virus vaccine live is usually administered through subcutaneous or intramuscular injection. After injection, the attenuated virus replicates in the body at a limited rate at the injection site.
Distribution:
The vaccine virus may disseminate from the injection site to other body parts through the lymphatic system. As the immune response is triggered, various immune cells, such as B-cells and T-cells, encounter the viral antigens and become activated, producing specific antibodies against the mumps virus.
Metabolism:
As a live vaccine, the mumps virus vaccine does not undergo typical metabolic processes like drugs. Instead, the attenuated virus replicates in a limited manner, serving as the antigen to stimulate the immune response. This immune response is what confers protection against mumps in the future.
Elimination and Excretion:
The attenuated rubella virus in the vaccine does not persist in the body indefinitely. Over time, the replication of the virus decreases, and it is eventually cleared from the body.
Administration:
Healthcare Setting: The mumps virus vaccine live is usually administered in a healthcare setting, such as a doctor’s office, clinic, or vaccination center. Trained healthcare professionals, such as nurses or doctors, perform the vaccination.
Age for Vaccination: The mumps virus vaccine live is commonly given to children as part of the recommended childhood vaccination schedule. It is often administered as part of a combination vaccine known as the measles, mumps, and rubella (MMR) or the measles, mumps, rubella, and varicella (MMRV) vaccine.
Booster Doses: In some countries, a mumps virus vaccine booster dose may be recommended for specific age groups or individuals. Booster doses help maintain long-term immunity against mumps.
Recommended Schedule: The recommended schedule for the mumps virus vaccine varies by country and health guidelines. In many countries, the first dose of the MMR or MMRV vaccine is given around 12 to 15 months, with a second dose between 4 and 6 years of age. However, specific recommendations may differ, so it is essential to follow the schedule local health authorities provide.
Catch-up Vaccination: Individuals who have not received the mumps virus vaccine during childhood can still get vaccinated. Catch-up vaccination may be recommended for adolescents and adults who did not receive the vaccine in childhood or have incomplete vaccination records.
Patient information leaflet
Generic Name: mumps virus vaccine, live
Pronounced as: mumps-VYE-rus-VAX-een, lyve
Why do we use the mumps virus vaccine live?
Prevention of mumps: The primary goal of administering the mumps virus vaccine is to prevent mumps infections. By vaccinating individuals against mumps, the vaccine helps reduce the virus’s spread in the population.
Control of Outbreaks: mumps is a highly contagious disease that can cause outbreaks, especially in communities with low vaccination rates. The vaccine plays a crucial role in controlling and preventing outbreaks, limiting the number of cases, and reducing transmission.
Herd Immunity: Widespread vaccination against mumps contributes to herd immunity. When a significant portion of the population is immune to the virus, it creates a protective barrier, reducing the likelihood of the virus spreading to vulnerable individuals who cannot receive the vaccine, such as those with weakened immune systems or certain medical conditions.
Prevention of Complications: mumps can lead to complications, particularly in adolescents and adults. These complications may include orchitis and oophoritis, meningitis (inflammation of the membranes surrounding the brain and spinal cord), and encephalitis (inflammation of the brain). Vaccination against mumps helps prevent these complications.
Long-Lasting Immunity: The mumps virus vaccine live elicits a robust and long-lasting immune response. After receiving the vaccine, most individuals develop protective immunity against mumps, lasting many years or even a lifetime.
Cost-Effective Public Health Measure: Vaccinating against mumps is a cost-effective public health intervention. It helps prevent the economic burden associated with mumps infections and its complications by reducing the need for medical care and hospitalization.
Induces Immune Response: When the mumps virus vaccine is administered, the attenuated virus replicates in the body at a limited rate. This limited replication is enough to trigger an immune response but not strong enough to cause mumps.
Humoral Immunity: The vaccine primarily stimulates the production of specific antibodies against the mumps virus. These antibodies, called anti-mumps antibodies, circulate in the bloodstream and target the virus, neutralizing and preventing its spread.
Cellular Immunity: Besides humoral immunity, the mumps vaccine induces cellular immune responses. This involves the activation of T-lymphocytes (T-cells) that recognize and destroy cells infected with the mumps virus, helping to clear the virus from the body.
Memory Immune Response: Like other live vaccines, the mumps virus vaccine live also induces memory immune responses. Memory B-cells and T-cells are formed during the immune response, providing long-term immunity against the mumps virus. These memory cells “remember” the virus and can rapidly mount a defense if the person is exposed to the virus in the future.
Spectrum:
The mumps virus vaccine live provides a broad spectrum of protection against mumps infection and its potential complications, which include:
Prevention of mumps: The primary action of the mumps virus vaccine is to prevent mumps infection. By developing immunity through vaccination, the body can effectively fight off the mumps virus if exposed to it in the future.
Parotitis Prevention: mumps typically causes painful swelling of the salivary glands, particularly the parotid glands, resulting in parotitis. The vaccine’s ability to prevent mumps reduces the risk of parotitis and its associated discomfort and complications.
Orchitis and Oophoritis Prevention: mumps can lead to complications like orchitis (inflammation of the testicles) in males and oophoritis (inflammation of the ovaries) in females. Vaccination against mumps helps prevent these complications.
Meningitis Prevention: In some cases, mumps can lead to viral meningitis, an inflammation of the membranes surrounding the brain and spinal cord. The vaccine reduces the risk of mumps-related viral meningitis by preventing mumps infection.
Dosing & Uses
Drug Interaction
Adverse Reaction
Frequency not defined
Erythema
Wheal
Pain
Erythema
Anaphylaxis
Vasculitis
Urticaria
Rash
Nausea
Pancreatitis
Purpura
Muscle pain
Black Box Warning
Black Box Warning:
None
Contraindication / Caution
Contraindication/Caution:
Contraindications:
Severe allergy
Immunodeficiency
Pregnancy
Cautions:
Recent blood product administration
History of thrombocytopenia
Mild to moderate illness
Pregnancy / Lactation
Pregnancy consideration:
US FDA Pregnancy category: C
Breastfeeding warnings:
The excretion of the drug in breast milk is unknown.
Pregnancy category:
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Pharmacology
Pharmacology:
Immunogenicity: The primary pharmacological action of the mumps virus vaccine live is its ability to induce an immune response. When the vaccine is administered, the weakened mumps virus replicates at a limited rate at the injection site.
Activation of Immune Response: The attenuated virus in the body triggers the immune system. The immune cells recognize the viral antigens and initiate an immune response against the virus.
Humoral Immunity: The vaccine primarily stimulates the production of specific antibodies against the mumps virus. These antibodies, known as anti-mumps antibodies, circulate in the bloodstream and other body fluids, targeting and neutralizing the virus.
Cellular Immunity: Besides humoral immunity, the mumps virus vaccine induces cellular immune responses. It activates T-lymphocytes (T-cells) that recognize and destroy cells infected with the mumps virus, helping to clear the virus from the body.
Memory Immune Response: Like other live vaccines, the mumps virus vaccine live induces memory immune responses. Memory B-cells and T-cells are formed during the immune response, providing long-term immunity against the mumps virus. These memory cells “remember” the virus and can rapidly mount a defense if the person is exposed to the virus in the future.
Top of Form
Pharmacodynamics:
Antigen Presentation: When the rubella virus vaccine is administered, the attenuated live virus replicates in the body at a limited rate. The viral particles are taken up by antigen-presenting cells (APCs).
Activation of Adaptive Immune Response: The antigen-presenting cells process the viral antigens and present them to T-lymphocytes (T-cells) and B-lymphocytes (B-cells). This interaction stimulates the adaptive immune response, which is highly specific to the rubella virus.
B-Cell Activation and Antibody Production: B-cells are activated by the presented antigens, leading to their proliferation and differentiation into plasma cells. Plasma cells secrete specific antibodies, called anti-rubella antibodies, into the bloodstream.
Humoral Immunity: The antibodies produced in response to the rubella virus vaccine are critical for humoral immunity. These antibodies circulate in the blood and other body fluids, ready to neutralize the rubella virus if it enters the body.
Memory Immune Response: One of the crucial aspects of the rubella vaccine life is its ability to induce memory immune responses. Memory B-cells and T-cells are formed during the immune response, providing long-term immunity against the rubella virus. These memory cells “remember” the rubella virus and can rapidly mount a defense if the individual is exposed to the virus again.
Cellular Immunity: Besides humoral immunity, the live rubella vaccine elicits cellular immune responses. T-cells play a crucial role in cellular immunity by recognizing and destroying cells infected with the rubella virus. This helps to clear the virus from the body and prevent its further spread.
Pharmacokinetics:
Absorption
The mumps virus vaccine live is usually administered through subcutaneous or intramuscular injection. After injection, the attenuated virus replicates in the body at a limited rate at the injection site.
Distribution:
The vaccine virus may disseminate from the injection site to other body parts through the lymphatic system. As the immune response is triggered, various immune cells, such as B-cells and T-cells, encounter the viral antigens and become activated, producing specific antibodies against the mumps virus.
Metabolism:
As a live vaccine, the mumps virus vaccine does not undergo typical metabolic processes like drugs. Instead, the attenuated virus replicates in a limited manner, serving as the antigen to stimulate the immune response. This immune response is what confers protection against mumps in the future.
Elimination and Excretion:
The attenuated rubella virus in the vaccine does not persist in the body indefinitely. Over time, the replication of the virus decreases, and it is eventually cleared from the body.
Adminstartion
Administration:
Healthcare Setting: The mumps virus vaccine live is usually administered in a healthcare setting, such as a doctor’s office, clinic, or vaccination center. Trained healthcare professionals, such as nurses or doctors, perform the vaccination.
Age for Vaccination: The mumps virus vaccine live is commonly given to children as part of the recommended childhood vaccination schedule. It is often administered as part of a combination vaccine known as the measles, mumps, and rubella (MMR) or the measles, mumps, rubella, and varicella (MMRV) vaccine.
Booster Doses: In some countries, a mumps virus vaccine booster dose may be recommended for specific age groups or individuals. Booster doses help maintain long-term immunity against mumps.
Recommended Schedule: The recommended schedule for the mumps virus vaccine varies by country and health guidelines. In many countries, the first dose of the MMR or MMRV vaccine is given around 12 to 15 months, with a second dose between 4 and 6 years of age. However, specific recommendations may differ, so it is essential to follow the schedule local health authorities provide.
Catch-up Vaccination: Individuals who have not received the mumps virus vaccine during childhood can still get vaccinated. Catch-up vaccination may be recommended for adolescents and adults who did not receive the vaccine in childhood or have incomplete vaccination records.
Patient Information Leaflet
Patient information leaflet
Generic Name: mumps virus vaccine, live
Pronounced as: mumps-VYE-rus-VAX-een, lyve
Why do we use the mumps virus vaccine live?
Prevention of mumps: The primary goal of administering the mumps virus vaccine is to prevent mumps infections. By vaccinating individuals against mumps, the vaccine helps reduce the virus’s spread in the population.
Control of Outbreaks: mumps is a highly contagious disease that can cause outbreaks, especially in communities with low vaccination rates. The vaccine plays a crucial role in controlling and preventing outbreaks, limiting the number of cases, and reducing transmission.
Herd Immunity: Widespread vaccination against mumps contributes to herd immunity. When a significant portion of the population is immune to the virus, it creates a protective barrier, reducing the likelihood of the virus spreading to vulnerable individuals who cannot receive the vaccine, such as those with weakened immune systems or certain medical conditions.
Prevention of Complications: mumps can lead to complications, particularly in adolescents and adults. These complications may include orchitis and oophoritis, meningitis (inflammation of the membranes surrounding the brain and spinal cord), and encephalitis (inflammation of the brain). Vaccination against mumps helps prevent these complications.
Long-Lasting Immunity: The mumps virus vaccine live elicits a robust and long-lasting immune response. After receiving the vaccine, most individuals develop protective immunity against mumps, lasting many years or even a lifetime.
Cost-Effective Public Health Measure: Vaccinating against mumps is a cost-effective public health intervention. It helps prevent the economic burden associated with mumps infections and its complications by reducing the need for medical care and hospitalization.
Loading...
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
